P81.02 Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors

Neoadjuvant therapy can improve outcome by increasing the resection rate, down staging the primary tumor and improving postoperative survival. PD-1/PD-L1 inhibitors have been approved in the treatment of advanced lung cancer, breast cancer, melanoma and other common cancers, and its success has moved immunotherapy forward to the early stage setting. In this study, we summarized the ongoing clinical trials which focus on neoadjuvant immunotherapy in solid cancers, and discussed their treatment strategy, efficacy and adverse events.